Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma by Wilson, Wyndham H. et al.
1228
ARTICLES
haematologica | 2014; 99(7)
Non-Hodgkin Lymphoma
Introduction 
Involvement of the central nervous system (CNS) is an
infrequent but often fatal complication of aggressive B-cell
lymphomas.1 It mostly presents as leptomeningeal disease
with involvement of the cerebrospinal fluid (CSF).  Although
prophylactic treatment likely reduces the incidence of CNS
relapse, it increases the toxicity of systemic chemotherapy
and is unnecessary in most patients.2,3 This has led to the
development of clinical risk paradigms to identify patients for
CNS prophylaxis, but only a few patients will potentially
benefit.1,4
Among patients who develop CNS disease, only a small
fraction have cytologically detectable malignant cells in the
CSF on initial staging.4 This observation raised the question of
whether cytology was unable to detect low volume disease or
if leptomeningeal spread was a late event.  Cytology of the
CSF, the diagnostic gold standard, however, has a low sensi-
tivity with a reported false negative rate of 20-60%, suggest-
ing pre-treatment leptomeningeal involvement is greater than
initially reported.5,6 Several studies now show that CSF flow
cytometry (FCM), which is significantly more sensitive than
cytology, detects a relatively high rate of occult disease.4,7,8
The ability to detect occult leptomeningeal involvement
early in the disease raises uncertainties regarding optimal
treatment.  FCM provides an opportunity to ’prospectively’
identify patients with leptomeningeal disease, thereby
enabling the assessment of intrathecal chemotherapy on CNS
recurrence and survival, which is an area of controversy.
Indeed, multiple retrospective studies have examined the
effect of systemic rituximab and intrathecal ‘prophylaxis’ on
the risk of CNS recurrence in DLBCL and have reported
inconsistent results.9-13 To help address these questions, we
conducted an analysis of untreated patients with DLBCL or
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The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk
of central nervous system disease is controversial.  Furthermore, the effect of intrathecal treatment and rituximab in
diffuse large B-cell and Burkitt lymphoma with occult leptomeningeal disease detected by flow cytometry at diagno-
sis is unknown. Untreated diffuse large B-cell (n=246) and Burkitt (n=80) lymphoma at clinical risk of central nervous
system disease and having had pre-treatment cerebrospinal fluid were analyzed by flow cytometry and cytology.
Spinal fluid involvement was detected by flow cytometry alone (occult) in 33 (13%) diffuse large B-cell and 9 (11%)
Burkitt lymphoma patients, and detected by cytology in 11 (4.5%) and 5 (6%) patients, respectively.  Diffuse large
B-cell lymphoma with occult spinal fluid involvement had poorer survival (P=0.0001) and freedom from central nerv-
ous system relapse (P<0.0001) compared to negative cases. Burkitt lymphoma with occult spinal fluid involvement
had an inferior freedom from central nervous system relapse (P=0.026) but not survival. The amount of intrathecal
chemotherapy was quantitatively associated with survival in diffuse large B-cell lymphoma with (P=0.02) and with-
out (P=0.001) occult spinal fluid involvement. However, progression of systemic disease and not control of central
nervous system disease was the principal cause of treatment failure. In diffuse large B-cell lymphoma, systemic rit-
uximab was associated with improved freedom from central nervous system relapse (P=0.003) but not with survival.
Our results suggest that patients at risk of central nervous system disease should be evaluated by flow cytometry and
that intrathecal prophylaxis/therapy is beneficial.
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BL at clinical risk of CNS disease who underwent FCM
and cytology of the CSF at initial staging.  We provide
new information on the effect of intrathecal chemothera-
py and systemic rituximab on the incidence of CNS recur-
rence and survival in patients at risk of CNS disease who
did and did not have evidence of occult CSF involvement
at initial diagnosis.  
Methods 
Eligibility 
This is an analysis of 326 patients with previously untreated
DLBCL and BL at clinical risk of CNS disease who had CSF analy-
sis by FCM and cytology at initial staging. Patients were retrospec-
tively identified between March 1999 and September 2010 from
the National Cancer Institute (one center); Spanish Group for the
Study of CNS Disease in non-Hodgkin lymphoma (NHL) (26 cen-
ters with the majority of cases from 4 centers); and Daniel den
Hoed Cancer Center (one center), Rotterdam, The Netherlands.
Patient eligibility included untreated disease, de novoDLBCL or BL
histology, and CSF FCM and cytology at initial diagnosis.  HIV-
positive patients have a similar outcome to HIV-negative patients
in the present era and these were included.14,15 DLBCL patients
were considered at risk of CNS disease as defined by the presence
of at least one extranodal site and elevated lactate dehydroge-
nase.1,4  In addition, patients with BL, HIV infection and/or patients
with neurological symptoms were considered at risk of CNS dis-
ease. Tumor histology was confirmed by each institution accord-
ing to the World Health Organization classification of lymphoid
tissue.16
Study design 
The primary objectives were: 1) to determine the incidence of
leptomeningeal lymphoma by CSF FCM and cytology at initial
diagnosis; 2) to assess freedom from CNS recurrence (FFCR) and
survival in patients with occult (FCM+/cytology-) CSF involve-
ment; 3) to assess the effect of intrathecal treatment and systemic
rituximab on FFCR and survival; and 4) to identify features associ-
ated with CSF involvement.
An Excel database was created to capture the following data
elements: patients’ characteristics, diagnosis, HIV status, dates of
treatment and response, systemic chemotherapy, amount and
type of intrathecal chemotherapy, CSF chemistry, FCM and cytol-
ogy, CNS response to treatment, and dates of CNS recurrence,
systemic recurrence, and/or death, and contributing institution.
The study was approved by the Institutional Review Board,
exempted from informed consent and the data were coded.
Statistics are described in the Online Supplementary Appendix. 
Flow cytometry 
Flow cytometry analysis complied with the International
Working Group on Flow Cytometric Immunophenotyping of the
CSF.17 The protocol is designed for 3-8 colors, depending on the
number of parameters available on the flow cytometer used. The
method can be applied to freshly obtained or stabilized samples.
Samples were processed within 1 h after lumbar puncture or sta-
bilized using TransFix® (Cytomark, UK) or RPMI transport medi-
um to avoid in vitro cell deterioration. The protocol describes the
simultaneous assessment of surface and cytoplasmic antigens, and
a method to calculate absolute numbers of both normal and
pathological cell subpopulations by adding counting beads to the
assay.  In most cases, clonal neoplastic cells were detected by the
presence of light chain restriction concordant with the primary
tumor, whereas malignant cells that did not express light chains
were detected by an abnormal B-cell phenotype concordant with
the primary tumor.4
Treatment  
Patients with DLBCL received standard doxorubicin-based reg-
imens as described in the Online Supplementary Appendix.18,19
Patients with Burkitt lymphoma received Burkitt regimens as
described in the Online Supplementary Appendix.20-22 Central nerv-




The study included 246 patients with DLBCL and 80
patients with BL who were at clinical risk of CNS disease.
Table 1. Patients’ characteristics at diagnosis.
Characteristics                                      DLBCL         Burkitt Lymphoma
                                                            Number (%)          Number (%)
Total Patients                                                      246                              80
Median Age  (Range)                                   54 (9-92)                 40 (18-88)
Age ≥ 60                                                           98 (40%)                  16 (20%)
Sex (Male)                                                     163 (66%)                 64 (80%)
Stage III/IV                                                     195 (79%)                 59 (74%)
Extranodal sites
0-1                                                                 148 (60%)                 47 (59%)
2-7                                                                  98 (40%)                  33 (41%)
Bone Marrow Involvement                          66 (27%)                  23 (29%)
LDH > Normal                                              140 (57%)                 50 (63%)
ECOG ≥ 2                                                        91 (37%)                  32 (40%)
International Prognostic Index
Low/low-intermediate (0-2)                     64 (26%)                  43 (54%)
High-intermediate/high (3-5)                  181 (74%)                 37 (46%)
HIV Serology (positive)                               56 (23%)                  21 (26%)
Accrual Center
National Cancer Institute                          75 (30%)                  31 (38%)
Spanish CNS Study Group                        145 (59%)                 42 (53%)
Netherlands Study Group                         26 (11%)                     7 (9%)
Table 2. Cerebrospinal spinal fluid malignant cell analysis. 
Cell detection method FCM+ FCM- Total P2 (FCM vs.
Cytology)
Diffuse large B-cell 
lymphoma
Cytology+ 9 2 11/246 < 0.0001
(4.5%)
Cytology- 33 202 235/246 
(95.5%)
Total 42/246 204/246 246
(17%) (83%)
Burkitt Lymphoma 
Cytology+ 4 1 5/80 0.02
(6%)
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Patients with DLBCL had a median age of 54 years (range
9-92 years) and 66% were male (Table 1). Clinical charac-
teristics associated with an increased risk of CNS disease
in DLBCL included 2 or more extranodal sites of disease in
40%, elevated LDH in 57%, and high-intermediate/high
international prognostic index score in 74%. BL patients
had a median age of 40 years (range 18-88 years) and 74%
had advanced stage disease, which is associated with a
risk of CNS disease.
Cerebrospinal fluid analysis 
Lymphoma was detected in the CSF by FCM in 42
(17%) patients and by cytology in 11 (4.5%) patients with
DLBCL (P<0.0001) (Table 2). All but 2 cases detected by
cytology were also detected by FCM, whereas cytology
only detected 26% of FCM-positive cases. Among
patients with BL, lymphoma was detected by FCM in 13
(16%) patents and by cytology in 5 (6%) patients (P=0.02).
Similarly, cytology only detected 31% of FCM-positive
cases in BL. HIV infection was not associated with an
increased incidence of leptomeningeal disease. 
We examined the association between brain parenchy-
mal disease and CSF involvement pretreatment. Ten (4%)
patients with DLBCL and 1 (1%) patient with BL had radi-
ological evidence of parenchymal involvement. Of these
cases, 4 (2%) patients, all with DLBCL, also had involve-
ment of the CSF, which was detected by FCM in 3 and by
cytology in 2 patients.
To determine if the presence of occult disease
(FCM+/cytology-) in the CSF was associated with
increased CSF protein or cell counts, we compared
patients with occult disease to patients without CSF
involvement. There was no significant difference in the
median (range) cell count (1.2 (0-26.9) and 0.9 (0-42);
P=0.054) or total protein (44 (9-109) and 33 (1-608);
P=0.077) in patients with or without occult CSF involve-
ment, respectively, consistent with the low tumor burden
of occult disease.
Outcome of cerebrospinal fluid involvement
Patients with DLBCL had an overall survival of 65% at
three years, and a median follow up of 50 months (Figure
1A).  Within the DLBCL patients, occult disease was asso-
ciated with lower survival (38% vs. 69% at 3 years;
P=0.0001) and freedom from CNS relapse (73% vs. 94% at
3 years; P<0.0001) compared to patients without CSF
involvement  (Figure 1B and C). The findings were statis-
tically similar when confined to the patients who received
systemic rituximab. There was no difference in survival
(P=0.54) or freedom from CNS relapse (P=0.72) among
patients with a positive compared to negative cytology.
Patients with BL had an overall survival of 83% at three-
years and a median follow up of 43 months (Figure 1D).
In BL, occult CSF involvement was associated with a
lower freedom from CNS relapse (78% vs. 98% at 3 years;
P=0.026) but not survival (Figure 1E and F). In contrast,
patients with a positive CSF cytology had a lower survival
compared to patients with a negative cytology (87% vs.
not reached at three years; P=0.005) but no difference in
freedom from CNS relapse (data not shown).
Effect of intrathecal chemotherapy and systemic
rituximab
To assess the effect of intrathecal chemotherapy on the
outcome of patients at risk of CNS involvement, we divid-
ed the patients into three risk groups; 1) occult CSF
involvement (FCM+/Cytology-); 2) cytology-positive CSF
(Cytology+/FCM +/-) and; 3) no CSF involvement (FCM-
/Cytology-) (Table 3). Within the group with occult CSF
involvement, all but 1 patient received active treatment
with intrathecal methotrexate (21%), cytarabine (24%) or
a combination of methotrexate, cytarabine and hydrocor-
tisone (Triple) (52%). Prophylactic intrathecal chemother-
apy was administered in 85% of patients who had no evi-
dence of CSF involvement. A minority of patients in both
groups received systemic methotrexate and/or cytarabine
as part of their systemic treatment (Table 3). 
To investigate quantitative effect of intrathecal therapy
on outcome, we divided each group into tertiles based on
the number of intrathecal doses (Table 4). Within the 33
patients with occult CSF disease, we observed an associa-
tion between the number of intrathecal doses and survival
(0% vs. 44% vs. 65% at three-years for 0-4, 5-6 and 7-26
doses, respectively) (P=0.02) but not with freedom from
CNS relapse (P=0.56) (Figure 2A and 2B). Seventy percent
of patients in the 0-4 dose had systemic disease failure
compared to only 23% and 36% of patients in the 5-6 and
7-26 dose tertile, respectively (Table 4). In contrast, the
CSF of most patients became flow negative including 63%
of patients in the first tertile who only received 0-4 doses.
Furthermore, the frequency of CSF and brain parenchymal
relapse was similar among tertiles. These results suggest
that among patients with occult CSF involvement, the
principal cause of treatment failure is systemic disease and
not CNS recurrence. Among 11 patients with cytology
positive CSF, all cleared their CSF and only 18% devel-
oped systemic disease (Table 4).
We also looked at the 201 patients at risk of CNS disease
and without evidence of CSF involvement by FCM and/or
cytology; 171 (85%) received at least 1 dose of intrathecal
chemotherapy (Table 3). In these patients, the number of
intrathecal doses was also significantly associated with
improved survival (76% vs. 75% vs. 57% at 3 years for 6-
24, 3-5 and 0-2 doses, respectively) (Table 4 and Figure 2C)
but not with freedom from CNS relapse (data not shown).
However, patients who received any intrathecal
chemotherapy had a significantly better freedom from
CNS relapse compared to patients who received no
intrathecal doses (Figure 2D). There was no significant dif-
ference in the incidence of systemic or CNS recurrence
among the three tertiles (Table 4). All three groups
received similar systemic methotrexate, cytarabine and/or
rituximab. 
We analyzed the survival and freedom from CNS
relapse of DLBCL patients who did or did not receive sys-
temic rituximab. Rituximab administration did not affect
overall survival, but significantly improved the freedom
from CNS relapse (93% vs. 76% at 4 years) (Figure 2E and
F).  Notably, there was no difference in the frequency of
intrathecal chemotherapy in the patients who did or did
not receive rituximab (P=1.00). We also looked at the sub-
group of patients who had CSF involvement pre treatment
to assess if rituximab improved the outcome of patients
with established CSF disease. For this analysis, we includ-
ed both DLBCL and BL patients with CSF involvement.
This analysis showed a significant association between
systemic rituximab and improved survival (54% vs. 14%;
P=0.025) and freedom from CNS relapse (85% vs. 34%;
P=0.0005) (Figure 2G and H).
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Figure 1. Kaplan-Meier plots of OS and FFCR of DLBCL and BL according to FCM and cytology CSF status. (A) OS of 246 patients with DLBCL.
(B) OS of 203 DLBCL patients without CSF involvement (FCM and/or cytology negative) and 33 DLBCL patients with occult CSF involvement
(FCM positive only). (C) FFCR of 203 DLBCL patients without CSF involvement and 33 DLBCL patients with occult CSF involvement. (D) OS of
80 BL patients. (E) OS of 66 BL patients without CSF involvement and 9 BL patients with occult CSF involvement (Exact log rank test).  
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Figure 2. Kaplan-Meier plots of OS and FFCR of DLBCL according to the amount of intrathecal chemotherapy doses and systemic rituximab.
(A) OS of 33 DLBCL patients with occult CSF involvement (FCM positive only) according to the number of intrathecal treatments divided into
tertiles. (B) FFCR of 33 DLBCL patients with occult CSF involvement (FCM positive only) according to the number of intrathecal doses divided
into tertiles. (C) OS of 201 DLBCL patients without CSF involvement according to the number of intrathecal treatments divided into tertiles. 
(D) FFCR of 201 DLBCL patients without CSF involvement according to according to the number of intrathecal treatments divided into tertiles.
(E) OS of DLBCL patients according to whether they did (n=231) or did not (n=15) receive systemic rituximab. (F) FFCR of DLBC patients accord-
ing to whether they did (n=231) or did not (n=15) receive systemic rituximab. (G) OS of 44 DLBCL and 13 BL patients with CSF involvement
according to whether they did (n=50) or did not (n=7) receive systemic rituximab. (H) FFCR of 44 DLBCL and 13 BL patients with CSF involve-
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Risk factors for CSF involvement by lymphoma
In a univariate analysis in DLBCL patients, extranodal
disease (P<0.0001), performance status (P=0.009), stage
(P=0.002) and international prognostic index (P<0.0001)
were associated with a positive CSF. However, multivari-
ate analysis only showed extranodal disease (P<0.0001)
and age (P=0.02) were independent predictors. In BL, only
disease stage (P=0.03) was associated with CSF involve-
ment in a univariate analysis. 
Discussion
The present analysis validates our previous findings that
FCM is significantly more sensitive than cytology for the
detection of CSF involvement by aggressive B-cell lym-
phoma, and indicates the presence of CSF involvement in
a high proportion of untreated patients at clinical risk for
CNS disease.4,7 The high sensitivity of FCM raises the
question of whether occult CSF involvement is clinically
meaningful. To address this question, we analyzed the
survival and freedom from CNS relapse of patients with
occult CSF involvement and compared them to patients
without evidence of CSF involvement. In DLBCL, patients
with occult CSF involvement had lower survival and free-
dom from CNS relapse compared to those without any
involvement. Occult CSF involvement in BL was also asso-
ciated with a lower freedom from CNS relapse, but not
survival. However, cytology was associated with a worse
survival in BL patients.  Several conclusions can be drawn
from these data.  In DLBCL, the majority of patients who
developed CNS recurrence appear to have occult CSF
involvement at initial diagnosis based on the reported fre-
quency of CNS recurrence.9,12,24  Furthermore, occult CSF
involvement is associated with a worse outcome, confirm-
ing it is a clinically meaningful and actionable finding. The
findings were somewhat different in BL, reflecting differ-
ences in disease biology and treatment.  In BL, cytology
but not FCM was significantly associated with overall sur-
vival. This may reflect the known ability of treatment to
control or sterilize leptomeningeal disease in BL, which
would be more likely in patients with occult levels of
involvement. 
Our study shows for the first time that occult lep-
tomeningeal disease is associated with an adverse out-
come in DLBCL and BL. These results are consistent with
several reports on the outcome of FCM+ CSF involvement
in pooled analyses of aggressive B-cell lymphomas.4,25,26
One small retrospective study showed an association
between occult CSF involvement and risk of CNS relapse,
and a second prospective study showed an adverse associ-
ation between FCM+ CSF and survival and risk of CNS
progression.25,26 
The benefit of intrathecal therapy is controversial in
DLBCL.9,13,24,27 The reasons for this controversy are multi-
factorial. To help address this question, we first looked at
patients with pre-treatment occult CSF involvement who
in the absence of FCM analysis would have been clinically
considered for prophylactic treatment. As there is no stan-
dard for the number of intrathecal doses in prophylactic or
active treatment, we took a quantitative approach by ana-
lyzing the clinical outcome according to the number of
intrathecal doses divided into tertiles. We observed a
quantitative association between the amount of intrathe-
cal chemotherapy and survival with 0-4 doses having a
worst outcome than at least 5-6 doses. Notably, FCM
showed a complete response in the CSF of most patients,
including 63% of patients who only received 0-4 doses.
Progression of systemic disease, which occurred in 70% of
patients who received 0-4 doses, was the principal cause
of treatment failure.  Overall, 74% of patients with occult
involvement achieved a complete remission by FCM in
their CSF, and only 9% relapsed in the CSF. We also
looked at patients without evidence of CSF involvement
and found a similar association between the amount of
intrathecal chemotherapy and survival. Like patients with
occult CSF disease, systemic progression and not CNS
progression was the principal cause of treatment failure.
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Table 3. DLBCL central nervous system treatment.
Treatment                                   Cerebrospinal fluid status
                            FCM+ and Cytology-   Cytology+   FCM- and Cytology-
                                        N=33              Cytology+             N=201
                                                                  N=11                      
IT treatment                                                                                               
Methotrexate                 7 (21%)                  2 (18%)                77 (38%)
Cytarabine                       8 (24%)                  3 (27%)                29 (14%)
Triple                               17 (52%)                 5 (45%)                65 (32%)
Systemic treatment                                                                                 
Methotrexate                   3 (9%)                   2 (18%)                 12 (6%)
Cytarabine                        6 (18%)                  3 (27%)                29 (14%)
Rituximab                        27 (82%)              11 (100%)             191 (95%)
IT: Intrathecal administration; Triple: methotrexate/cytarabine/hydrocortisone.
Table 4. Outcome of intrathecal treatment in DLBCL.
Intrathecal dose groups Outcome
FCM+ and Response Sites of treatment failure 
Cytology- (N=33) in CSF
Cleared Systemic Brain CSF
0-4 63% 70% 20% 10%
(N=10: median 2) (5/8) (7/10) (2/10) (1/10)
5-6 77% 23% 23% 8%
(N=13: median 6) (10/13) (3/13) (3/13) (1/13)
7-26 80% 20% 0% 11%
(N=10: median 15.5) (8/10) (2/10) (0/10) (1/9)
Total 74% 36% 15% 9%
(23/31) (12/33) (5/33) (3/32)
Cytology + Cleared Systemic Brain CSF
(N=11) 
0-15 100% 18% 10% 0%
(median 3) (10/10) (2/11) (1/10) (0/10)
FCM- and Cleared Systemic Brain CSF
Cytology- (N=201)
0-2 NA 23% 3% 5%
(N=69: median 1) (16/69) (2/69) (3/62)
3-5 
(N=59: median 3) NA 12% 1.7% 0%
(7/59) (1/59) (0/55)
6-24 
(N=73: median 6) NA 15% 6% 3.5%
(11/72) (4/72) (2/57)
Total NA 17% 3.5% 2.9%
(34/200) (7/200) (5/174)
These results show that intrathecal therapy controls CNS
disease in most patients and in this regard confers benefit.
Our results also suggest that the biology associated with
CNS disease leads to a higher risk of systemic disease fail-
ure in some patients.
The effect of systemic rituximab on the risk of CNS
relapse is also controversial.9-13 To assess this, we looked
at the effect of rituximab on survival and freedom from
CNS relapse. Within all patients with DLBCL, systemic
rituximab was associated with a significant reduction in
CNS relapse suggesting it may treat established CNS dis-
ease. Alternatively, systemic rituximab may reduce the
secondary spread of lymphoma to the CNS and not
directly affect established CNS disease due to its poor
CNS penetration.28 To address this issue, we assessed the
effect of systemic rituximab on the outcome of patients
with pretreatment CSF involvement. In this analysis,
which included DLBCL and BL, we observed a signifi-
cant association between systemic rituximab and
improved survival and freedom from CNS relapse, sug-
gesting that systemic rituximab has therapeutic effects
on established CSF disease. It is important to note, how-
ever, that most patients also received intrathecal
chemotherapy, precluding any conclusion that rituximab
alone can eradicate CNS disease.
The low incidence of CNS disease in DLBCL, clinically
observed in 5% of unselected patients and 8% of high-risk
patients, has made it difficult to study the benefit of CNS
prophylaxis.1,2,29 In the pre-rituximab era, a randomized
study of CHOP versus ACVBP (doxorubicin; cyclophos-
phamide; vindesine; bleomycin; prednisone; and intrathe-
cal treatment) in poor prognosis aggressive lymphomas
showed a significantly lower incidence of CNS recurrence
on the ACVBP arm where CNS-directed therapy was
used, suggesting benefit.2 However, several retrospective
rituximab-era studies in DLBCL did not find a benefit of
intrathecal prophylaxis.9,10,13,27 Two studies from the
German High-Grade Non-Hodgkin Lymphoma Study
Group (DSHNHL) reported that CNS prophylaxis was of
no significant benefit in high-risk young patients or elderly
patients with aggressive B-cell lymphoma.13,27 The conclu-
sions are confounded by two methodological problems.
First, patients were designated to receive intrathecal pro-
phylaxis based on clinical criteria that were inconsistent
with the authors’ own optimal risk model for CNS dis-
ease. Second, the authors compared the patients in this
‘high-risk’ group who received intrathecal prophylaxis
with those who did not (due to a protocol violation).
Hence, patients at high risk of CNS disease were not opti-
mally identified and the control group was biased with
patients who the treating physicians felt did not need pro-
phylaxis. Unfortunately, another large negative database
study had related methodological issues.9
Our results provide the first evidence that occult CSF
involvement by DLBCL or BL is clinically meaningful and
associated with an adverse outcome. Intrathecal therapy
was associated with excellent control of CNS disease and
systemic progression was the main cause of treatment fail-
ure. Finally, our results suggest that systemic rituximab has
therapeutic activity against established CSF disease and
reduces CNS relapse. These results indicate that patients at
risk of CNS disease will benefit from intrathecal
chemotherapy, although the optimal therapy remains to be
determined. Based on these results, we suggest that patients
at risk of CNS disease undergo evaluation of the CSF by
FCM, and that patients receive prophylactic or therapeutic
CNS-directed chemotherapy, as indicated by the absence or
presence of leptomeningeal disease, respectively. 
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